Diosmetin

Name: Diosmetin
Brand: MedChemExpress
SKU: HY-N0125
Rating: 5.0 (20 reviews)

Cat. No.: HY-N0125 Purity: 99.71%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity with an IC₅₀ of 40 μM in HepG2 cell.

For research use only. We do not sell to patients.

CAS No. : 520-34-3

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 20 publication(s) in Google Scholar

Other Forms of Diosmetin:

Diosmetin-d₃ In-stock
Diosmetin (Standard) In-stock

20 Publications Citing Use of MCE Diosmetin

Cell Proliferation/Viability Assay

Cell Migration/Invasion Assay

Histological Imaging/Staining

Others

: Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]; IC50 values of ESCC cells after 48 h of Diosmetin (DIOS) treatment.

: Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]; Effects of Diosmetin (DIOS) pretreated ESCC cell conditioned medium (CM) on migration, invasion, and tubular formation of human umbilical vein endothelial cells (HUVECs).

: Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]; The expression levels of p-PI3K Tyr458, p-AKT Ser473, p-STAT4 Tyr693, and PDGFC, as well as the secretion level of PDGFC, were detected in ESCC cells after Diosmetin (DIOS) intervention.

: Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]; Diosmetin (DIOS: 40 μM). Immunohistochemical staining image of CD31 in glue plug tissue.

: Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]; SPR experiments showed that Diosmetin (DIOS: 40 μM) can bind directly to AURKB.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity with an IC₅₀ of 40 μM in HepG2 cell.

IC₅₀ & Target

CYP1

Cellular Effect

Cell Line	Type	Value	Description	References
HT-22	EC₅₀	59.7 μM Compound: 12	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
HUVEC	IC₅₀	7.6 μM Compound: 40, diosmetin	Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells	10.1007/s00044-012-0353-y
HepG2	EC₅₀	7.98 μM Compound: Diosmetin	Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay	[PMID: 26974372]
K562	IC₅₀	8.42 μM Compound: Diosmetin	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay	[PMID: 35551036]
KBM5	IC₅₀	6.46 μM Compound: Diosmetin	Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay	[PMID: 35551036]
KBM5	IC₅₀	8.52 μM Compound: Diosmetin	Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay	[PMID: 35551036]
Monocyte	IC₅₀	3 x 10^-6 M Compound: diosmetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Neutrophil	IC₅₀	0.7 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	10.3 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	15 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	3.6 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Peritoneal macrophage	IC₅₀	8.9 μM Compound: 28; kp18	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
RAW264.7	CC₅₀	> 100 μM Compound: 19	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33667099]
RAW264.7	IC₅₀	16.7 μM Compound: 28; kp18	Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	32.2 μM Compound: 28; kp18	Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	34.5 μM Compound: 19	Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 33667099]
RAW264.7	IC₅₀	8.4 μM Compound: 10	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]

In Vitro

Diosmetin inhibits cell proliferation in HepG2 cells in a concentration-dependent manner. Untreated HepG2 cells grow well and are observed to have with normal skeletons, whereas cells treated with diosmetin are distorted and a number of them become round and floating^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pretreatment with diosmetin significantly reduces serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-κB activation in cerulein-induced acute pancreatitis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

300.26

Formula

C₁₆H₁₂O₆

CAS No.

520-34-3

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (333.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3304 mL	16.6521 mL	33.3041 mL
5 mM	0.6661 mL	3.3304 mL	6.6608 mL
10 mM	0.3330 mL	1.6652 mL	3.3304 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (33.30 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.71%

Select Batch:

Data Sheet (277 KB) SDS (396 KB)

COA (248 KB) HNMR (159 KB) RP-HPLC (256 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Liu B, et al. Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells. Mol Med Rep. 2016 Jul;14(1):159-64. [Content Brief]

[2]. Yu G, et al. Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2133-42. [Content Brief]

Cell Assay ^[1]	Diosmetin is dissolved in DMSO which is maintained at a constant concentration in control samples (2%). HepG2 cells are maintained in a humidified atmosphere of 5% CO₂ at 37°C, and cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin and 100 U/mL streptomycin. HepG2 cell density is adjusted to 2×10⁴ cells/100 μL, and the cells are seeded into 96-well plates and placed in an incubator overnight (37°C in 5% CO₂) to allow for attachment and recovery. MTT analyses are performed. Briefly, cells are pretreated with 5, 10, 15 and 20 μg/mL diosmetin for 24 h. A total of 20 μL MTT solution (5 mg/mL in PBS) solution is transferred to each well to yield a final 120 μL/well and to separate wells a total of 10 μL CCK8 (5 mg/mL in PBS) is transferred. The plates are incubated for 4 h at 37°C in 5% CO₂ and the absorbance is recorded at wavelengths of 595 nm and 450 nm, respectively. The half maximal inhibitory concentration (IC₅₀) of diosmetin is calculated^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Experimental acute pancreatitis is induced in mice by seven intraperitoneal injection of cerulein (50 μg/kg) at hourly intervals. Diosmetin (100 mg/kg) or vehicle is pretreated 2 h before the first cerulein injection. After 6 h, 9 h, 12 h of the first cerulein injection, the severity of acute pancreatitis is evaluated biochemically and morphologically^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Liu B, et al. Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells. Mol Med Rep. 2016 Jul;14(1):159-64. [Content Brief] [2]. Yu G, et al. Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2133-42. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3304 mL	16.6521 mL	33.3042 mL	83.2604 mL
	5 mM	0.6661 mL	3.3304 mL	6.6608 mL	16.6521 mL
	10 mM	0.3330 mL	1.6652 mL	3.3304 mL	8.3260 mL
	15 mM	0.2220 mL	1.1101 mL	2.2203 mL	5.5507 mL
	20 mM	0.1665 mL	0.8326 mL	1.6652 mL	4.1630 mL
	25 mM	0.1332 mL	0.6661 mL	1.3322 mL	3.3304 mL
	30 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	40 mM	0.0833 mL	0.4163 mL	0.8326 mL	2.0815 mL
	50 mM	0.0666 mL	0.3330 mL	0.6661 mL	1.6652 mL
	60 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL
	80 mM	0.0416 mL	0.2082 mL	0.4163 mL	1.0408 mL
	100 mM	0.0333 mL	0.1665 mL	0.3330 mL	0.8326 mL

Diosmetin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Diosmetin520-34-3Cytochrome P450CYPsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Diosmetin

Customer Review

Other Forms of Diosmetin:

Diosmetin Related Antibodies

20 Publications Citing Use of MCE Diosmetin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Diosmetin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Diosmetin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report